McGonigle K F, Lantry S A, Odom-Maryon T L, Chai A, Vasilev S A, Simpson J F
Department of Gynecology, City of Hope National Medical Center, Duarte, CA 91010-0269, USA.
Cancer Lett. 1996 Mar 19;101(1):59-66. doi: 10.1016/0304-3835(96)04114-6.
We evaluated the histopathologic changes of the uterine epithelium in 73 breast cancer patients with tamoxifen stratified by menopausal status. Clinicopathologic data at the time of breast cancer diagnosis and endometrial sampling were analyzed and compared with 122 breast cancer patients not receiving the drug. The incidence of endocervical and/or endometrial polyps was increased in tamoxifen-treated postmenopausal patients compared with untreated patients, 43% (25 of 58) and 24% (16 of 68), respectively (odds ratio=2.46, P=0.02). In contrast, there was no increase in polyps in premenopausal tamoxifen-treated patients. This finding suggests that the effects of tamoxifen on the endometrium may vary with menopausal status.
我们评估了73例接受他莫昔芬治疗的乳腺癌患者子宫上皮的组织病理学变化，并根据绝经状态进行了分层。分析了乳腺癌诊断时和子宫内膜取样时的临床病理数据，并与122例未接受该药物治疗的乳腺癌患者进行了比较。与未治疗的患者相比，他莫昔芬治疗的绝经后患者宫颈内膜和/或子宫内膜息肉的发生率有所增加，分别为43%（58例中的25例）和24%（68例中的16例）（优势比=2.46，P=0.02）。相比之下，绝经前接受他莫昔芬治疗的患者息肉没有增加。这一发现表明，他莫昔芬对子宫内膜的影响可能因绝经状态而异。
